Trial
NCT01803269
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Chicago
Collaborators
National Cancer Institute (NCI)
Condition
Extensive Stage Small Cell Lung Cancer
Intervention
topotecan hydrochloride
Why stopped
Due to lack of activity and slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-26